p21 regulates expression of ECM components and promotes pulmonary fibrosis via CDK4 and Rb

Nurit Papismadov,Naama Levi,Lior Roitman,Amit Agrawal,Yossi Ovadya,Ulysse Cherqui,Reut Yosef,Hagay Akiva,Hilah Gal,Valery Krizhanovsky
DOI: https://doi.org/10.1038/s44318-024-00246-7
2024-10-01
The EMBO Journal
Abstract:Fibrosis and accumulation of senescent cells are common tissue changes associated with aging. Here, we show that the CDK inhibitor p21 (CDKN1A), known to regulate the cell cycle and the viability of senescent cells, also controls the expression of extracellular matrix (ECM) components in senescent and proliferating cells of the fibrotic lung, in a manner dependent on CDK4 and Rb phosphorylation. p21 knockout protects mice from the induction of lung fibrosis. Moreover, inducible p21 silencing during fibrosis development alleviates disease pathology, decreasing the inflammatory response and ECM accumulation in the lung, and reducing the amount of senescent cells. Furthermore, p21 silencing limits fibrosis progression even when introduced during disease development. These findings show that one common mechanism regulates both cell cycle progression and expression of ECM components, and suggest that targeting p21 might be a new approach for treating age-related fibrotic pathologies.
cell biology,biochemistry & molecular biology
What problem does this paper attempt to address?